Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol
Background: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia. Patients and method...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2005-12, Vol.16 (12), p.1928-1935 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1935 |
|---|---|
| container_issue | 12 |
| container_start_page | 1928 |
| container_title | Annals of oncology |
| container_volume | 16 |
| creator | Diviné, M. Casassus, P. Koscielny, S. Bosq, J. Sebban, C. Le Maignan, C. Stamattoulas, A. Dupriez, B. Raphaël, M. Pico, J.-L. Ribrag, V. |
| description | Background: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia. Patients and methods: Treatment began with a prephase (low-dose steroids, vincristine and cyclophosphamide), except in patients with low tumor burden. Group A (resected stage I and abdominal stage II disease) received three courses of vincristine, cyclophosphamide, doxorubicin and prednisone. Group B (not eligible for groups A or C) received five courses of chemotherapy comprising high-dose methotrexate, infusional cytarabine and intrathecal (IT) methotrexate. Group C (patients with central nervous system and/or bone marrow involvement with |
| doi_str_mv | 10.1093/annonc/mdi403 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19747149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19747149</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-c4171372f74a310cf6ec7b76ab19e3dbae37a7b8d13974e4d9f1279bb1453d053</originalsourceid><addsrcrecordid>eNpdkd1rVDEQxYNY7Lr66KsEQd9um6-bbHxrq3UrKyIoFF_C3CSXpr1fJrna_e_NsosLvmQI85szwzkIvaLkjBLNz2EYxsGe9y4Iwp-gBa2lrlZE0KdoQTTjlaq5OEXPU7onhEjN9DN0SiVbCVKrBeov5_gQcsbdtp_uxh5wGDC4ucvpPQY8xTFN3ubw2-OUZ7fFY4sVwxPk4IeccI4esnf4T8h3GHajMO3-k3cBcgwWb75c7mTyaMfuBTppoUv-5aEu0Y_rj9-v1tXm66ebq4tNZUUtc3mpolyxVgnglNhWeqsaJaGh2nPXgOcKVLNylGslvHC6pUzppqGi5o7UfIne7XXL4l-zT9n0IVnfdTD4cU6GljFFhS7gm__A-3GOQ7mtMFIySYuFS1TtIVvcSNG3Zoqhh7g1lJhdCGYfgtmHUPjXB9G56b070gfXC_D2AECy0LURBhvSkVNcacbUcXFI2T_-60N8MLIwtVnf_jSf6bf69lquzQf-F_ShoNo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196626192</pqid></control><display><type>article</type><title>Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Diviné, M. ; Casassus, P. ; Koscielny, S. ; Bosq, J. ; Sebban, C. ; Le Maignan, C. ; Stamattoulas, A. ; Dupriez, B. ; Raphaël, M. ; Pico, J.-L. ; Ribrag, V.</creator><creatorcontrib>Diviné, M. ; Casassus, P. ; Koscielny, S. ; Bosq, J. ; Sebban, C. ; Le Maignan, C. ; Stamattoulas, A. ; Dupriez, B. ; Raphaël, M. ; Pico, J.-L. ; Ribrag, V. ; GELA ; GOELAMS</creatorcontrib><description>Background: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia. Patients and methods: Treatment began with a prephase (low-dose steroids, vincristine and cyclophosphamide), except in patients with low tumor burden. Group A (resected stage I and abdominal stage II disease) received three courses of vincristine, cyclophosphamide, doxorubicin and prednisone. Group B (not eligible for groups A or C) received five courses of chemotherapy comprising high-dose methotrexate, infusional cytarabine and intrathecal (IT) methotrexate. Group C (patients with central nervous system and/or bone marrow involvement with <30% of blast cells) received eight courses containing intensified high-dose methotrexate, high-dose cytarabine, etoposide and triple IT injections. Results: The 2 year event-free survival and overall survival rates for the 72 patients were 65% and 70%, respectively. Age ≥33 years and high lactate dehydrogenase value were associated with a shorter survival. No response to COP was also associated with a poor outcome in group B. Conclusion: Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdi403</identifier><identifier>PMID: 16284057</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adolescent ; Adult ; adult patients ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Burkitt lymphoma ; Burkitt Lymphoma - drug therapy ; Burkitt Lymphoma - mortality ; Burkitt Lymphoma - pathology ; chemotherapy ; Cyclophosphamide - therapeutic use ; Cytarabine - therapeutic use ; Disease-Free Survival ; Doxorubicin - therapeutic use ; Etoposide - therapeutic use ; Female ; Hematologic and hematopoietic diseases ; Humans ; Hydrocortisone - therapeutic use ; Leucovorin - therapeutic use ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Methotrexate - therapeutic use ; Middle Aged ; Neoplasm Staging ; Pharmacology. Drug treatments ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology ; Prednisone - therapeutic use ; Prognosis ; prognostic factors ; Prospective Studies ; Survival Rate ; Vincristine - therapeutic use</subject><ispartof>Annals of oncology, 2005-12, Vol.16 (12), p.1928-1935</ispartof><rights>2006 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Dec 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-c4171372f74a310cf6ec7b76ab19e3dbae37a7b8d13974e4d9f1279bb1453d053</citedby><cites>FETCH-LOGICAL-c456t-c4171372f74a310cf6ec7b76ab19e3dbae37a7b8d13974e4d9f1279bb1453d053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17379227$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16284057$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Diviné, M.</creatorcontrib><creatorcontrib>Casassus, P.</creatorcontrib><creatorcontrib>Koscielny, S.</creatorcontrib><creatorcontrib>Bosq, J.</creatorcontrib><creatorcontrib>Sebban, C.</creatorcontrib><creatorcontrib>Le Maignan, C.</creatorcontrib><creatorcontrib>Stamattoulas, A.</creatorcontrib><creatorcontrib>Dupriez, B.</creatorcontrib><creatorcontrib>Raphaël, M.</creatorcontrib><creatorcontrib>Pico, J.-L.</creatorcontrib><creatorcontrib>Ribrag, V.</creatorcontrib><creatorcontrib>GELA</creatorcontrib><creatorcontrib>GOELAMS</creatorcontrib><title>Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia. Patients and methods: Treatment began with a prephase (low-dose steroids, vincristine and cyclophosphamide), except in patients with low tumor burden. Group A (resected stage I and abdominal stage II disease) received three courses of vincristine, cyclophosphamide, doxorubicin and prednisone. Group B (not eligible for groups A or C) received five courses of chemotherapy comprising high-dose methotrexate, infusional cytarabine and intrathecal (IT) methotrexate. Group C (patients with central nervous system and/or bone marrow involvement with <30% of blast cells) received eight courses containing intensified high-dose methotrexate, high-dose cytarabine, etoposide and triple IT injections. Results: The 2 year event-free survival and overall survival rates for the 72 patients were 65% and 70%, respectively. Age ≥33 years and high lactate dehydrogenase value were associated with a shorter survival. No response to COP was also associated with a poor outcome in group B. Conclusion: Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.</description><subject>Adolescent</subject><subject>Adult</subject><subject>adult patients</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Burkitt lymphoma</subject><subject>Burkitt Lymphoma - drug therapy</subject><subject>Burkitt Lymphoma - mortality</subject><subject>Burkitt Lymphoma - pathology</subject><subject>chemotherapy</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Cytarabine - therapeutic use</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin - therapeutic use</subject><subject>Etoposide - therapeutic use</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Hydrocortisone - therapeutic use</subject><subject>Leucovorin - therapeutic use</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Pharmacology. Drug treatments</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology</subject><subject>Prednisone - therapeutic use</subject><subject>Prognosis</subject><subject>prognostic factors</subject><subject>Prospective Studies</subject><subject>Survival Rate</subject><subject>Vincristine - therapeutic use</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkd1rVDEQxYNY7Lr66KsEQd9um6-bbHxrq3UrKyIoFF_C3CSXpr1fJrna_e_NsosLvmQI85szwzkIvaLkjBLNz2EYxsGe9y4Iwp-gBa2lrlZE0KdoQTTjlaq5OEXPU7onhEjN9DN0SiVbCVKrBeov5_gQcsbdtp_uxh5wGDC4ucvpPQY8xTFN3ubw2-OUZ7fFY4sVwxPk4IeccI4esnf4T8h3GHajMO3-k3cBcgwWb75c7mTyaMfuBTppoUv-5aEu0Y_rj9-v1tXm66ebq4tNZUUtc3mpolyxVgnglNhWeqsaJaGh2nPXgOcKVLNylGslvHC6pUzppqGi5o7UfIne7XXL4l-zT9n0IVnfdTD4cU6GljFFhS7gm__A-3GOQ7mtMFIySYuFS1TtIVvcSNG3Zoqhh7g1lJhdCGYfgtmHUPjXB9G56b070gfXC_D2AECy0LURBhvSkVNcacbUcXFI2T_-60N8MLIwtVnf_jSf6bf69lquzQf-F_ShoNo</recordid><startdate>20051201</startdate><enddate>20051201</enddate><creator>Diviné, M.</creator><creator>Casassus, P.</creator><creator>Koscielny, S.</creator><creator>Bosq, J.</creator><creator>Sebban, C.</creator><creator>Le Maignan, C.</creator><creator>Stamattoulas, A.</creator><creator>Dupriez, B.</creator><creator>Raphaël, M.</creator><creator>Pico, J.-L.</creator><creator>Ribrag, V.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20051201</creationdate><title>Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol</title><author>Diviné, M. ; Casassus, P. ; Koscielny, S. ; Bosq, J. ; Sebban, C. ; Le Maignan, C. ; Stamattoulas, A. ; Dupriez, B. ; Raphaël, M. ; Pico, J.-L. ; Ribrag, V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-c4171372f74a310cf6ec7b76ab19e3dbae37a7b8d13974e4d9f1279bb1453d053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>adult patients</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Burkitt lymphoma</topic><topic>Burkitt Lymphoma - drug therapy</topic><topic>Burkitt Lymphoma - mortality</topic><topic>Burkitt Lymphoma - pathology</topic><topic>chemotherapy</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Cytarabine - therapeutic use</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin - therapeutic use</topic><topic>Etoposide - therapeutic use</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Hydrocortisone - therapeutic use</topic><topic>Leucovorin - therapeutic use</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Pharmacology. Drug treatments</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology</topic><topic>Prednisone - therapeutic use</topic><topic>Prognosis</topic><topic>prognostic factors</topic><topic>Prospective Studies</topic><topic>Survival Rate</topic><topic>Vincristine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Diviné, M.</creatorcontrib><creatorcontrib>Casassus, P.</creatorcontrib><creatorcontrib>Koscielny, S.</creatorcontrib><creatorcontrib>Bosq, J.</creatorcontrib><creatorcontrib>Sebban, C.</creatorcontrib><creatorcontrib>Le Maignan, C.</creatorcontrib><creatorcontrib>Stamattoulas, A.</creatorcontrib><creatorcontrib>Dupriez, B.</creatorcontrib><creatorcontrib>Raphaël, M.</creatorcontrib><creatorcontrib>Pico, J.-L.</creatorcontrib><creatorcontrib>Ribrag, V.</creatorcontrib><creatorcontrib>GELA</creatorcontrib><creatorcontrib>GOELAMS</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Diviné, M.</au><au>Casassus, P.</au><au>Koscielny, S.</au><au>Bosq, J.</au><au>Sebban, C.</au><au>Le Maignan, C.</au><au>Stamattoulas, A.</au><au>Dupriez, B.</au><au>Raphaël, M.</au><au>Pico, J.-L.</au><au>Ribrag, V.</au><aucorp>GELA</aucorp><aucorp>GOELAMS</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2005-12-01</date><risdate>2005</risdate><volume>16</volume><issue>12</issue><spage>1928</spage><epage>1935</epage><pages>1928-1935</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia. Patients and methods: Treatment began with a prephase (low-dose steroids, vincristine and cyclophosphamide), except in patients with low tumor burden. Group A (resected stage I and abdominal stage II disease) received three courses of vincristine, cyclophosphamide, doxorubicin and prednisone. Group B (not eligible for groups A or C) received five courses of chemotherapy comprising high-dose methotrexate, infusional cytarabine and intrathecal (IT) methotrexate. Group C (patients with central nervous system and/or bone marrow involvement with <30% of blast cells) received eight courses containing intensified high-dose methotrexate, high-dose cytarabine, etoposide and triple IT injections. Results: The 2 year event-free survival and overall survival rates for the 72 patients were 65% and 70%, respectively. Age ≥33 years and high lactate dehydrogenase value were associated with a shorter survival. No response to COP was also associated with a poor outcome in group B. Conclusion: Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>16284057</pmid><doi>10.1093/annonc/mdi403</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2005-12, Vol.16 (12), p.1928-1935 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19747149 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult adult patients Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Burkitt lymphoma Burkitt Lymphoma - drug therapy Burkitt Lymphoma - mortality Burkitt Lymphoma - pathology chemotherapy Cyclophosphamide - therapeutic use Cytarabine - therapeutic use Disease-Free Survival Doxorubicin - therapeutic use Etoposide - therapeutic use Female Hematologic and hematopoietic diseases Humans Hydrocortisone - therapeutic use Leucovorin - therapeutic use Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Methotrexate - therapeutic use Middle Aged Neoplasm Staging Pharmacology. Drug treatments Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Prednisone - therapeutic use Prognosis prognostic factors Prospective Studies Survival Rate Vincristine - therapeutic use |
| title | Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T13%3A22%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Burkitt%20lymphoma%20in%20adults:%20a%20prospective%20study%20of%2072%20patients%20treated%20with%20an%20adapted%20pediatric%20LMB%20protocol&rft.jtitle=Annals%20of%20oncology&rft.au=Divine%CC%81,%20M.&rft.aucorp=GELA&rft.date=2005-12-01&rft.volume=16&rft.issue=12&rft.spage=1928&rft.epage=1935&rft.pages=1928-1935&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdi403&rft_dat=%3Cproquest_cross%3E19747149%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196626192&rft_id=info:pmid/16284057&rfr_iscdi=true |